Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of... It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
- Mechanism
- Curator reviewed
ATYR1923 acts to reduce overall inflammation and fibrotic deposition in the lungs, stabilizing its function; it acts as a disease modifying therapy for people with interstitial lung disease (ILD). The mechanism behind this is that the drug selectively binds to and regulates NRP2, reducing its innate and adaptive immune response pathways associated with cytokine and chemokine production and T-cell activation.
- Also known as
- Human IgG1Fc- iMod domain (amino acids 2-60) of human HARS fusion protein
- Code names
- ATYR-1923
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with Efzofitimod, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account